Global /India /Healthcare /Drug Manufacturers - Specialty & Generic /AUROPHARMA
chevron_leftBack

Aurobindo Pharma Ltd.

AUROPHARMA
NSE: AUROPHARMA Delayed
1,246.80INR 5%
14.58 USD
As of 24 April 2025, Aurobindo Pharma Ltd. has a market cap of $8.08B USD, ranking #2006 globally and #140 in India. It ranks #174 in the Healthcare sector, and #26 in the Drug Manufacturers - Specialty & Generic industry.
Global Rank
2006
Country Rank
140
Sector Rank
174
Industry Rank
26
Key Stats
Market Cap
$8.08BUSD
689.82B INR
Enterprise Value
$8.25BUSD
705.47B INR
Revenue (TTM)
$3.62BUSD
309.22B INR
EBITDA (TTM)
$768.61MUSD
65.72B INR
Net Income (TTM)
$409.13MUSD
34.91B INR
EBITDA Margin
21%
Profit Margin
11%
PE Ratio
19.9
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Kambam Reddy open_in_new
Employees
26,015
Founded
1986
Website
aurobindo.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
5% 4.7% -1.1% 0.1% -19% 9.3%
Upcoming Earnings
Earnings Date
Wed, May 28

Markets

Exchange Ticker Price
National Stock Exchange of India
MIC: XNSE
PRIMARY
AUROPHARMA
Aurobindo Pharma Ltd
ISIN: INE406A01037
Shares Out.:
580.802M1 Shares Float: 274.147M2
TV:
SA:
YF:
GF:
BA:
MS:
1.25K INR
Bombay Stock Exchange
MIC: XBOM
524804 (AUROPHARMA)
Aurobindo Pharma Ltd
ISIN: INE406A01037
TV:
SA:
YF:
GF:
BA:
MS:
1.17K INR
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Aurobindo Pharma Ltd.

Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin’s, cephalosporins, penems, and non-beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

Similar Companies

Industry: Drug Manufacturers - Specialty & Generic (India)
Name
Market Cap diff.
Sun Pharmaceutical Industries Ltd.
SUNPHARMA
$49.13B
4.19T INR
508%
Divi's Laboratories Ltd.
DIVISLAB
$18.39B
1.57T INR
127%
Cipla Ltd.
CIPLA
$14.46B
1.23T INR
79%
Torrent Pharmaceuticals Ltd.
TORNTPHARM
$13.23B
1.13T INR
64%
Mankind Pharma Ltd.
MANKIND
$12.47B
1.06T INR
54%
Industry: Drug Manufacturers - Specialty & Generic (Global)
Name
Market Cap diff.
Zoetis Inc.
ZTS
$67.32B
733%
Merck KGaA
MRK
$59.42B
52.43B EUR
635%
Takeda Pharmaceutical Company Ltd.
4502
$46.31B
6.6T JPY
473%
Haleon plc
HLN
$45.57B
34.34B GBP
464%
Galderma Group AG
GALD
$23.06B
19.13B CHF
185%